Clinical Trials | November 27, 2025
Otsuka files FDA application for first-in-class ADHD drug
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
A key highlight will be Brenntag’s qualified amino acids portfolio
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
Millions of stroke survivors across the world may soon have a new defense
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated
